Patents Assigned to Integrated DNA Technologies, Inc.
  • Publication number: 20130345291
    Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.
    Type: Application
    Filed: September 6, 2013
    Publication date: December 26, 2013
    Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
    Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
  • Publication number: 20130236967
    Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
    Type: Application
    Filed: February 25, 2013
    Publication date: September 12, 2013
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, Kimberly Ann Lennox, Ashley Mae Jacobi, Richard Owczarzy, Joseph Alan Walder
  • Publication number: 20130116415
    Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
    Type: Application
    Filed: January 9, 2013
    Publication date: May 9, 2013
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventor: Integrated DNA Technologies, Inc.
  • Patent number: 8399197
    Abstract: The invention provides compositions and methods for amplifying nucleic acid polymer sequences in a high complexity nucleic acid sample. The unique compositions of the invention include a primer set composed of a mixture of two types of primers for DNA synthesis. For extension in one direction, the primers all contain modifications that destroy their ability to serve as templates that can be copied by DNA polymerases. For extension in the opposite direction the set includes at least one primer that can serve as a template and be replicated by DNA polymerases throughout its length. The method can be carried out by mixing the nucleic acid polymer sequence of interest with the set of DNA synthesis primers in an amplification reaction mixture. The reaction mixture is then subjected to temperature cycling analogous to the temperature cycling in PCR reactions. At least one primer in the primer set hybridizes to the nucleic acid polymer.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: March 19, 2013
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mark Aaron Behlke, Joseph Alan Walder, Jeffrey A. Manthey
  • Patent number: 8377641
    Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 19, 2013
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
  • Publication number: 20120258535
    Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
    Type: Application
    Filed: June 8, 2012
    Publication date: October 11, 2012
    Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
    Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
  • Publication number: 20120258455
    Abstract: The present invention provides methods of cleaving a nucleic acid strand to initiate, assist, monitor or perform biological assays.
    Type: Application
    Filed: March 23, 2012
    Publication date: October 11, 2012
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, Scott D. Rose, Joseph Dobosy, Joseph Alan Walder
  • Patent number: 8258276
    Abstract: A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 4, 2012
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
  • Publication number: 20120123751
    Abstract: The invention relates to methods and systems for predicting or estimating the melting temperature of duplex nucleic acids, in the presence of divalent cations, particularly duplexes of oligonucleotides which may be used as, for example, but not limited to primers or probes in PCR and/or hybridization assays. The methods and algorithms use novel formulas, having terms and coefficients that are functions of the particular nucleotide sequence, to estimate the effect of divalent cation salt conditions on the melting temperature.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 17, 2012
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Richard Owczarzy, Bernardo Moreira, Yong You, Mark Aaron Behlke, Joseph Alan Walder
  • Publication number: 20120108799
    Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
    Type: Application
    Filed: September 7, 2011
    Publication date: May 3, 2012
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, Richard Owczarzy, Yong You, Joseph Alan Walder, Kim Lennox
  • Publication number: 20120064633
    Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
    Type: Application
    Filed: November 17, 2011
    Publication date: March 15, 2012
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
  • Patent number: 8129517
    Abstract: The disclosed invention pertains to improved oligonucleotide manufacturing methods, including novel support compositions that are optionally labeled, their methods of preparation and use. The compositions and methods are particularly well suited for high throughput oligonucleotide manufacturing in that the automated support recognition facilitates loading of the wells with the proper supports. In addition, the labeled supports can be used to confirm that each well of a multi-well plate, such as a 96 or 384 well plate, was properly loaded.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: March 6, 2012
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Yakov A. Letuchy, William E. Martin, David W. Muller, Shawn Allen, Shawn P. Walsh
  • Patent number: 8114979
    Abstract: The invention provides novel anthraquinone compositions that are useful as broad-spectrum quenchers of fluorescence and provides methods for making and using them. The anthraquinone quenchers can be conjugated to a variety of biologically relevant compounds, including lipids, nucleic acids, polypeptides, and more specifically antigens, steroids, vitamins, drugs, haptens, metabolites, toxins, environmental pollutants, amino acids, peptides, proteins, nucleotides, oligonucleotides, polynucleotides, carbohydrates, and their analogs. The invention also provides kits comprising, in one or more containers, at least one anthraquinone quencher dye composition of the present invention, and instructions for using that composition.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: February 14, 2012
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Andrei Laikhter, Mark Aaron Behlke, Yawfui Yong, Scott Rose, Lingyan Huang
  • Publication number: 20120029891
    Abstract: The present invention provides methods that more accurately predict melting temperatures for duplex oligomers. The invented methods predict the Tm of chimeric duplexes containing various amounts of locked nucleic acid modifications in oligonucleotide strands.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 2, 2012
    Applicant: Integrated DNA Technologies, Inc.
    Inventors: Mark Behlke, Richard Owczarzy, Scott D. Rose, Andrey Tataurov, Yong You
  • Patent number: 8106175
    Abstract: This invention pertains to methods for cloning microRNA (miRNA) and other small ribonucleic acid (RNA) species from relevant cell sources.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: January 31, 2012
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Eric J. Devor, Lingyan Huang, Mark A. Behlke
  • Publication number: 20110319606
    Abstract: A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile.
    Type: Application
    Filed: September 2, 2011
    Publication date: December 29, 2011
    Applicant: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
  • Patent number: 8084588
    Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: December 27, 2011
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
  • Patent number: 8084599
    Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: December 27, 2011
    Assignees: City of Hope, Integrated DNA Technologies, Inc.
    Inventors: John J. Rossi, Mark A. Behlke, Dongho Kim
  • Publication number: 20110301229
    Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
    Type: Application
    Filed: July 8, 2011
    Publication date: December 8, 2011
    Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
    Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
  • Publication number: 20110301224
    Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.
    Type: Application
    Filed: July 8, 2011
    Publication date: December 8, 2011
    Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
    Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM